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Background 
Typhoid and paratyphoid fevers can kill people. In the 
past, chloramphenicol, ampicillin, and cotrimoxazole 
were effective, but multiple-drug resistant (MDR) strains 
of the bacteria have emerged. Thus newer antibiotics 
may be better, particularly azithromycin, 
fluoroquinolones, and cephalosporins. 
Inclusion criteria 
Studies:  
Randomized controlled trials  
Participants: 
People with typhoid or paratyphoid fever confirmed by 
culture of S Typhi or S Paratyphi from blood, stool, urine 
or bone marrow.   
Intervention: 
Intervention: oral azithromycin.  
Control: any other antibiotic drug. 
Outcomes: 
Clinical or microbiological treatment failure, fever 
clearance time, duration of hospital stay, relapse within 
30 days, adverse events. 
Results 
Seven trials involving 773 participants were included; all 
were adequately concealed. All trials were conducted in 
low or middle-income countries, and included some 
participants with MDR strains.  
• Compared with chloramphenicol, no significant 
difference in treatment failure was detected with 
azithromycin in one small trial (77 participants). 
• Compared with fluoroquinolones, azithromycin 
performed better, with fewer clinical failures (odds 
ratio 0.48, 95% confidence interval 0.26 to 0.89; 564 
participants, 4 trials), and shorter mean stay in hospital 
(mean difference -1.04 days, 95% CI -1.73 to -0.34 
days; 213 participants, 2 trials), but there were no 
differences in microbiological failure, relapse, or fever 
clearance time. 
• Compared with cefriaxone, azithromycin performed 
better in relation to relapse (OR 0.09, 95% CI 0.01 to 
0.70; 132 participants, 2 trials), but there were no 
differences in clinical or microbiological failure, or 
fever clearance time. 
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Is azithromycin better than current first-line treatments 
for typhoid and paratyphoid fever? 
Azithromycin is at least as good as fluoroquinolones, but more expensive. 
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Authors’ conclusions 
Implications for practice:  
Azithromycin performs as well as fluoroquinolones for most outcomes, and may be better at reducing clinical 
treatment failures and length of hospital stay. Azithromycin also appears to be as effective as cefriaxone, although 
there is less evidence for this comparison. There is not enough evidence to compare azithromycin with first-line 
antibiotics currently used.    
Implications for research: 
More trials are needed to determine whether azithromycin is better than first line antibiotics, as these are cheaper 
and have fewer reported adverse events. 
Azithromycin vs floroquinolones: clinical failure 
 
